<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03097796</url>
  </required_header>
  <id_info>
    <org_study_id>PUL-042-201A</org_study_id>
    <secondary_id>R44HL127677</secondary_id>
    <nct_id>NCT03097796</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients</brief_title>
  <official_title>An Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of PUL-042 Inhalation Solution in Subjects With Hematologic Malignancies and Recipients of Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulmotect, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Prevention Research Institute of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pulmotect, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with hematologic malignancies or recipients of a first allogenic or autologus&#xD;
      hematopoietic stem cell transplant, without any evidence or respiratory infection, will&#xD;
      receive 4 doses of PUL-042 Inhalation Solution over a 2 week period. Subjects will be&#xD;
      evaluated for tolerability of the drug. If tolerated, dose escalation may occur with up to 4&#xD;
      dose levels tested&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label multiple ascending dose study with a 3+3 study design to examine the&#xD;
      safety and tolerability of PUL-042 Inhalation Solution in subjects with hematologic&#xD;
      malignancies or recipients of a first allogenic or autologus hematopoietic stem cell&#xD;
      transplant. Subjects will receive 4 doses over 2 weeks.&#xD;
&#xD;
      Cohort size will be 3 subjects, once 3 subjects have completed treatment and follow-up at a&#xD;
      dose level, subject data will be evaluated by an independent data safety monitoring committee&#xD;
      prior to dosing additional subjects. The Committee may recommend increasing the dose,&#xD;
      maintaining the same dose, or decreasing the dose.&#xD;
&#xD;
      Once the maximum dose is determined, there may be up to 6 additional subjects dosed at that&#xD;
      level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Protocol revision&#xD;
  </why_stopped>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in one Second (FEV1)</measure>
    <time_frame>3 weeks</time_frame>
    <description>Evaluation of increasing doses of PUL-042 Inhalation Solution on FEV1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum proteomics</measure>
    <time_frame>3 weeks</time_frame>
    <description>Evalution of increasing doses of PUL-042 Inhalation Solution on serum proteomic profile</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Hematologic Diseases</condition>
  <condition>Stem Cell Transplants</condition>
  <arm_group>
    <arm_group_label>PUL-042</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PUL-042 Inhalation Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PUL-042</intervention_name>
    <description>PUL-042 Inhalation Solution</description>
    <arm_group_label>PUL-042</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with hematologic malignancies or recipients of a first allogeneic or&#xD;
             autologous hematopoietic stem cell transplantation and presently clinically stable&#xD;
&#xD;
          2. Pulse oximetry of hemoglobin saturation ≥92% on room air&#xD;
&#xD;
          3. Adult (≥18 years)&#xD;
&#xD;
          4. Spirometry (FEV1 and forced vital capacity [FVC]) ≥80% of predicted value&#xD;
&#xD;
          5. If female, must be either post-menopausal (one year or greater without menses),&#xD;
             surgically sterile, or, for female subjects of child-bearing potential who are capable&#xD;
             of conception must be: practicing two effective methods of birth control&#xD;
&#xD;
          6. If female, must not be pregnant, plan to become pregnant, or nurse a child during the&#xD;
             study and through 30 days after completion of the study&#xD;
&#xD;
          7. If male, must be surgically sterile or willing to practice two effective methods of&#xD;
             birth control&#xD;
&#xD;
          8. Ability to understand and give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with any evidence of respiratory infection including any signs or symptoms of&#xD;
             either a lower respiratory infection (LRI) or upper respiratory infection (URI)&#xD;
&#xD;
          2. Known history of chronic pulmonary disease&#xD;
&#xD;
          3. Subjects who are being treated for fungal, viral, or bacterial pneumonia&#xD;
&#xD;
          4. Exposure to any investigational agent (defined as any agent not approved by the Food&#xD;
             and Drug Administration [FDA]) within 30 days prior to the Screening Visit&#xD;
&#xD;
          5. Patients with a relapsed and/or refractory underlying hematologic malignancy&#xD;
&#xD;
          6. HSCT recipients who underwent ex vivo T-cell depletion of the graft, or a mismatched,&#xD;
             or cord or haplo identical blood transplantation&#xD;
&#xD;
          7. HSCT recipients with active and/or chronic graft versus host disease&#xD;
&#xD;
          8. Patients on systemic corticosteroids (oral or intravenous)&#xD;
&#xD;
          9. Absolute neutrophil count (ANC) &lt; 1,000 cells/mL&#xD;
&#xD;
         10. Clinically significant bacteremia or fungemia&#xD;
&#xD;
         11. Current smokers or subjects with any history of smoking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy F Chemaly, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2017</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pam2CSK4 acetate and ODN M362 combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

